Application of SCARF1 inhibitors in the preparation of anti-breast cancer drugs
By targeting and downregulating SCARF1 gene expression and using a targeted nanomedicine delivery system, the problems of unclear molecular mechanisms and insufficient sensitivity of nanomedicines in breast cancer brain metastasis have been solved, achieving effective treatment and extended survival for breast cancer brain metastasis.
Patent Information
- Application Number
- CN202611263642.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-19
- Publication Date
- 2026-11-17
AI Technical Summary
The molecular mechanisms of breast cancer brain metastasis are not well understood in existing technologies, and there is a lack of effective strategies to increase the sensitivity of nanomedicines, which limits the efficacy of nanomedicines in treating breast cancer brain metastasis.
By identifying SCARF1 as a prognostic biomarker for breast cancer, we specifically inhibited SCARF1 gene expression and combined it with a targeted nanomedicine delivery system, including the preparation of the targeted nanodelivery drug MSN-DOX@PR, to downregulate SCARF1 expression and enhance the sensitivity of tumor cells to nanomedicines.
It significantly inhibits the proliferation and migration of brain metastases from breast cancer, enhances the enrichment and uptake of nanomedicines at the tumor site, and prolongs the survival of tumor-bearing mice, breaking through the efficacy bottleneck of nanotherapy for brain metastases from breast cancer.
Smart Images

Figure CN123108145A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical gene therapy and anti-breast cancer drug sensitization technology, specifically involving the application of SCARF1 inhibitors in the preparation of anti-breast cancer drugs. Background Technology
[0002] The information disclosed in this background section is intended only to enhance understanding of the overall background of the invention and is not necessarily to be construed as an admission or in any way implying that such information constitutes prior art known to those skilled in the art.
[0003] Breast cancer (BC) is the most common malignant tumor in women, posing a serious threat to women's health worldwide. Distant metastasis is the leading cause of death in these patients, with approximately 30% eventually developing brain metastases. Breast cancer brain metastases (BCBM) have a poor prognosis and high mortality rate; the median survival for patients with triple-negative breast cancer brain metastases is only 4.4 months. Currently, clinical treatment primarily involves surgery, radiotherapy, and chemotherapy. However, surgery is difficult to apply to multiple or deep lesions, and the objective response rates of chemotherapy and radiotherapy are low.
[0004] Compared to traditional drugs, designed and functionalized nanomedicines can achieve targeted delivery, local accumulation, and controlled release of drugs, thus significantly improving treatment precision. Furthermore, nanomedicines, with their unique enhanced penetration and retention effects, can selectively accumulate at tumor sites, enhancing efficacy while reducing damage to normal tissues. However, the use of nanomedicines in treating brain metastases of breast cancer is limited by multiple factors, including the lack of highly effective targeted drugs, the blood-brain barrier, and low drug uptake rates within tumor cells. Therefore, a strategy to enhance the sensitivity of tumor cells to nanomedicines is urgently needed to improve the effectiveness of nanotherapy.
[0005] m5C methylation is a key post-transcriptional RNA modification that can influence tumorigenesis and development by dynamically regulating RNA stability, translation, and localization. In our previous study, we systematically screened and identified differentially expressed RNAs with m5C methylation modifications between breast cancer brain metastases 231-BR cells and their parental cells MDA-MB-231 by integrating m5C MeRIP-seq and RNA-seq data. Among them, Scavenger receptor class F member 1 (SCARF1) was identified as one of the key molecules exhibiting both differential methylation and differential expression. SCARF1, also known as the endothelial cell scavenger receptor, is an 86 kDa type I transmembrane protein. It is known to play a role in the stable adhesion phase of the leukocyte adhesion cascade and can mediate endocytosis by binding to heat shock protein-associated antigens. In breast cancer research, it has been reported that estrogen receptor β2 (ERβ2) can inhibit the proliferation, migration, and invasion of triple-negative breast cancer cells by binding to the SCARF1 promoter and regulating the expression of the circular RNA hsa_circ_0000732. However, the specific function and mechanism of SCARF1 in breast cancer brain metastasis remains unclear.
[0006] Therefore, it is urgent to develop a synergistic therapeutic strategy that can inhibit brain metastasis of breast cancer while enhancing the sensitivity of tumor cells to nanomedicines. Summary of the Invention
[0007] This invention addresses the shortcomings of existing technologies, such as the unclear molecular mechanisms of brain metastasis and proliferation in cancers, particularly breast cancer, and the lack of effective techniques to increase the sensitivity of nanomedicines. It investigates the progression mechanism of breast cancer brain metastasis and provides a novel synergistic therapeutic approach that inhibits tumor growth and increases nanomedicine sensitivity. Firstly, this invention clarifies that SCARF1, as a dual target for tumor inhibition and nanomedicine enhancement, plays a crucial role in the treatment of breast cancer brain metastases. Secondly, this invention verifies the feasibility of synergistic therapy combining specific inhibition of SCARF1 with targeted drugs.
[0008] Based on the above-mentioned achievements, the present invention provides the following technical solution: Firstly, it provides the application of SCARF1 as a prognostic biomarker for breast cancer.
[0009] This invention provides the application of the SCARF1 gene or its expression product as a prognostic biomarker for breast cancer, specifically the application of the SCARF1 gene or its expression product in the preparation of breast cancer prognostic assessment reagents / kits; the breast cancer is preferably triple-negative breast cancer, more preferably triple-negative breast cancer with brain metastasis.
[0010] This invention, through clinical tissue sample verification and in vitro and in vivo functional experiments, confirms that the mRNA and protein expression levels of SCARF1 in brain metastases of breast cancer are significantly higher than those in primary breast cancer tissue. The expression level of SCARF1 is positively correlated with tumor cell proliferation, migration and invasion, and tumorigenicity in vivo. High SCARF1 expression indicates higher tumor malignancy, greater risk of brain metastasis, and shorter progression-free survival and overall survival in patients.
[0011] The specific applications cover the following scenarios: 1) Assessing the long-term brain metastasis risk of breast cancer patients, conducting key follow-up monitoring of SCARF1 high-expression populations, and achieving early warning of metastasis; 2) Determining the prognosis of breast cancer patients and assisting clinicians in risk stratification and disease management; 3) Guiding the selection of clinical treatment plans, and prioritizing the development of SCARF1-targeted intervention combined with nanochemotherapy for SCARF1 high-expression patients.
[0012] Samples for detecting SCARF1 expression levels can be selected from paraffin-embedded breast cancer tissue, fresh surgical tumor tissue, peripheral blood, serum, or plasma exosomes of the subjects; detection methods include, but are not limited to, immunohistochemistry, real-time quantitative PCR, Western blotting, transcriptome sequencing, and enzyme-linked immunosorbent assay.
[0013] Secondly, a polynucleotide that specifically downregulates SCARF1 expression, the nucleotide sequence of which is shown in SEQ ID NO:1.
[0014] The aforementioned polynucleotide that specifically downregulates SCARF1 gene expression encodes the DNA sequence of a short hairpin RNA (shRNA) targeting the human SCARF1 gene; its sequence is as follows: 5'-ccggGGGTGACAGTCTCACATCACGctcgagCGTGATGTGAGACTGTCACCCtttttg-3' The sequence, from the 5' end to the 3' end, contains, in sequence: a vector cloning adaptor sequence, a SCARF1-targeting sense strand sequence, a loop sequence (ctcgag), a SCARF1-targeting antisense strand sequence, and a Pol III promoter transcription termination sequence (tttttg). After being transferred into host cells, it is transcribed into a stem-loop shRNA precursor, which is then cleaved by the intracellular Dicer enzyme into mature siRNA. This siRNA specifically recognizes and degrades SCARF1 mRNA through RNA interference, thereby stably downregulating SCARF1 gene expression and protein synthesis at the post-transcriptional level. Cellular-level validation showed that this polynucleotide-mediated SCARF1 mRNA knockdown efficiency can reach over 70%, stably inhibiting SCARF1 protein expression in triple-negative breast cancer brain metastases.
[0015] Thirdly, a construct for inhibiting or downregulating SCARF1 expression, said construct being constructed by inserting the polynucleotide of the second aspect into the multiple cloning site of an expression vector.
[0016] The construct can be obtained by methods such as in vitro recombinant DNA technology, DNA synthesis technology, and in vivo recombination technology. More specifically, it can be constructed by inserting the isolated polynucleotides into the multiple cloning site of the expression vector. Further, the expression vector is a eukaryotic expression vector specifically for shRNA, preferably a lentiviral shuttle vector. The construct is constructed as follows: the sense and antisense oligonucleotides shown in SEQ ID NO: 1, synthesized chemically, are annealed to form a double-stranded DNA fragment. This fragment is then digested with restriction endonuclease and ligated with T4 DNA ligase, and inserted into the multiple cloning site downstream of the U6 promoter of the lentiviral shuttle vector. After sequencing verification confirms the correct insertion sequence and reading frame, the recombinant construct inhibiting SCARF1 expression is obtained.
[0017] Fourthly, a recombinant vector for inhibiting or downregulating SCARF1 expression, said recombinant vector comprising the polynucleotide of the second aspect or the construct of the third aspect.
[0018] The recombinant vectors in this invention include, but are not limited to, plasmid vectors, lentiviral vectors, adenovirus vectors, adeno-associated virus vectors, and retroviral vectors, with lentiviral vectors being preferred.
[0019] Fifthly, a nano-delivered drug, the method for preparing the nano-delivered drug comprising the following steps: (1) Preparation of silica nanoparticles: hexadecyltrimethylammonium chloride was used as a template agent and triethylamine as an alkaline catalyst. The mixture was dispersed in ultrapure water and heated and stirred. Then, tetraethyl orthosilicate was added dropwise to carry out hydrolysis and polycondensation reaction. After centrifugation, washing and drying, silica nanoparticles (MSN) were obtained. (2) Doxorubicin loading: The obtained silica nanoparticles and doxorubicin were dispersed in ultrapure water, stirred at room temperature in the dark to carry out drug adsorption loading, and the precipitate was collected by centrifugation to obtain drug-loaded nanoparticles (MSN-DOX). (3) Polydopamine coating: The MSN-DOX obtained in step (2) was resuspended in buffer solution, dopamine was added, and the mixture was stirred at room temperature in the dark to allow dopamine to polymerize in situ on the surface of the nanoparticles to form a polydopamine coating. The precipitate was collected by centrifugation to obtain polydopamine-coated drug-loaded nanoparticles (MSN-DOX@PDA). (4) Targeted ligand modification: Thiol-modified polyethylene glycol-modified RGD peptide (SH-PEG-RGD) was added to the MSN-DOX@PDA and surface covalent grafting reaction was carried out by stirring at room temperature in the dark. After the reaction was completed, the RGD targeted nano-delivery drug (MSN-DOX@PR) was obtained by centrifugation and purification.
[0020] In step (1) above, there is also the following preferred solution: Furthermore, the molar ratio of hexadecyltrimethylammonium chloride, triethylamine, and tetraethyl orthosilicate is 10~14:1:10~14, more preferably 12:1:12.5.
[0021] Further, the hexadecyltrimethylammonium chloride and triethylamine are thoroughly mixed in water at 80-100°C, and then tetraethyl silicate is slowly added to continue the reaction for 0.5-2 hours. After the reaction is completed, the reaction system is centrifuged to obtain the precipitate, which is the silica nanoparticle.
[0022] In step (2) above, there is also the following preferred solution: Furthermore, the mass ratio of the silica nanoparticles to doxorubicin is 0.8~1.2:0.8~1.2.
[0023] Furthermore, the stirring time in the dark is 3-5 hours.
[0024] In step (3) above, there is also the following preferred solution: Furthermore, the mass ratio of MSN-DOX to dopamine is 0.8~1.2:0.8~1.2, more preferably 1:1; the in-situ polymerization reaction time is 3~5h, more preferably 4h.
[0025] Furthermore, the stirring loading time in the dark is 18~30 h, more preferably 24 h.
[0026] In step (4) above, there is also the following preferred solution: Furthermore, the mass ratio of the thiol-modified polyethylene glycol-modified RGD peptide to the silica nanoparticles is 0.8~1.2:0.8~1.2.
[0027] Furthermore, in the thiol-modified polyethylene glycol-based RGD peptide, the polyethylene glycol segment has a molecular weight of 1000~3000 Da, more preferably 2000 Da.
[0028] Furthermore, the covalent grafting reaction time is 5-7 h, more preferably 6 h.
[0029] In addition, in steps (3) and (4) above, the buffer, for example, Tris-HCl buffer, preferably has a pH of 8 to 9.
[0030] Sixthly, a pharmaceutical composition comprising a therapeutically effective dose of an active ingredient and a pharmaceutically acceptable carrier; said active ingredient being selected from any one or more combinations of: the polynucleotide that specifically downregulates SCARF1 as described in the second aspect, the nucleic acid construct as described in the third aspect, the recombinant carrier as described in the fourth aspect, and the nanodelivery drug as described in the fifth aspect.
[0031] The pharmaceutical compositions described in this invention are suitable for subjects and can produce effects of prevention, improvement or treatment of related diseases. In this pharmaceutical composition, the dosage of the polynucleotide, construct, recombinant carrier or nanodelivered drug varies depending on the purpose of administration, which is technical content that can be routinely determined by those skilled in the art based on the prior art.
[0032] The pharmaceutical compositions described above also include pharmaceutically acceptable carriers in the art, the types of which include, but are not limited to, buffers (such as acetates, Tris, phosphates, citrates, and other organic acids), antioxidants (such as ascorbic acid and methionine), preservatives (such as octadecyl dimethyl benzyl ammonium chloride, phenol, butanol or benzyl alcohol, methylparaben or propylparaben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol), bactericides (such as chlorhexidine, benzalkonium chloride, and benzyl chloride), tension modifiers (such as trehalose and sodium chloride), sugars (such as sucrose, mannitol, trehalose, or sorbitol), surfactants (such as polysorbate), metal complexes (such as Zn-protein complexes), and / or nonionic surfactants (such as polyethylene glycol).
[0033] In a seventh aspect, the use of the SCARF1 inhibitor, the polynucleotide described in the second aspect, the construct described in the third aspect, the recombinant vector described in the fourth aspect, the nanodelivery drug described in the fifth aspect, and the pharmaceutical composition described in the sixth aspect in the preparation of an anti-breast cancer drug is provided.
[0034] The SCARF1 inhibitors include, but are not limited to, solid compounds, amino acids, nucleic acid components, or combinations thereof capable of silencing, downregulating, or inhibiting SCARF1 expression activity at the lesion site of the subject; the nucleic acid components include reagents for reducing SCARF1 activity based on genetic engineering methods, such as plasmids, lentiviruses, adenoviruses, etc. In a specific embodiment, the subject is a breast cancer patient, and the lesion site refers to the cancerous tissue of the breast cancer patient. In one embodiment verified by this invention, a shRNA that specifically downregulates SCARF1 is provided, the sequence of which is shown in SEQ ID NO:1. Obtaining the corresponding shRNA reagent based on this sequence is not technically difficult for those skilled in the art; feasible methods include commissioning a reagent company to synthesize it.
[0035] The breast cancer in question is further described as triple-negative breast cancer, and even further, as triple-negative breast cancer with brain metastasis.
[0036] The anti-breast cancer drugs include at least two of the following: (1) Drugs that inhibit the progression of brain metastases in breast cancer; (2) Drugs that enhance the sensitivity of tumor cells to nanomedicines.
[0037] In some embodiments verified by the present invention, the anti-breast cancer drug is a SCARF1 inhibitor, and further, it is the polynucleotide described in the second aspect, the construct described in the third aspect, or the recombinant vector described in the fourth aspect.
[0038] In other embodiments, the anti-breast cancer drug is a combination of a SCARF1 inhibitor and a breast cancer treatment drug, wherein the breast cancer treatment drug can be an existing drug clinically used for breast cancer treatment, or it can be the nanodelivered drug described in the fifth aspect.
[0039] The drug is administered to mammals, preferably humans; the drug can be administered via intravenous injection, intratumoral injection, intrathecal injection, etc., for the prevention and treatment of triple-negative breast cancer and breast cancer brain metastases.
[0040] Compared with the prior art, the beneficial effects of the present invention are: 1. This invention is the first to clearly identify SCARF1 as a key regulatory target for brain metastasis in triple-negative breast cancer. Integrating m5C MeRIP-seq and transcriptome sequencing, this invention is the first to screen SCARF1 as a key differentially expressed molecule in brain metastasis from both epigenetic modification and gene expression dimensions, confirming its significant high expression in both brain metastatic cells and clinical lesions. In vitro and in vivo functional validation showed that downregulating SCARF1 significantly inhibits tumor cell proliferation and migration, regulates adhesion-related molecules, and weakens invasiveness, effectively inhibiting tumor growth in vivo. This study fills a gap in research on epigenetic targets in breast cancer brain metastasis, providing novel target selection and theoretical support for precision medicine.
[0041] 2. In response to the above findings, this invention also provides a polynucleotide that specifically inhibits SCARF1, offering a highly efficient and stable tool for SCARF1 gene intervention. Verification has shown that this reagent achieves a knockdown efficiency of over 70% on SCARF1 mRNA, with a clear downregulation effect at the protein level. This provides a reliable experimental tool for target function research and lays a core material foundation for subsequent gene therapy drug development.
[0042] 3. This invention also verifies the feasibility of the SCARF1 downregulation synergistic targeted nanochemotherapy regimen. In vivo experiments have confirmed that the combination of the two can exert a dual effect of direct tumor inhibition and drug sensitization. Compared with single treatment, it significantly inhibits tumor growth and prolongs the survival of tumor-bearing mice, breaking through the technical bottleneck of limited efficacy of nanotherapy for brain metastases of breast cancer, and has good prospects for clinical translation. Attached Figure Description
[0043] The accompanying drawings, which form part of this invention, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an improper limitation of the invention.
[0044] Figure 1 The figure shows the experimental results of transcriptome + m5C modification in breast cancer (BCBM brain metastasis / BC primary) as described in Example 1; in, Figure 1 A in the image is a heatmap showing differential mRNA gene expression between 231-BR cells and MDA-MB-231 cells. Figure 1 In diagram B, we have a Venn diagram of differentially expressed genes and differentially expressed genes with m5C modification obtained from transcriptome sequencing. Figure 1 C represents the results of qPCR validation of SCARF1 upregulation; Figure 2 These are tissue sections of breast cancer brain metastases and primary breast cancer as described in Example 1; in Figure 2 Image A is a low-magnification tissue section of primary breast cancer. Figure 2Image B is a low-magnification tissue section of a brain metastasis lesion from breast cancer. Figure 2 The image in center C is a high-magnification view of the primary breast cancer area. Figure 2 Middle D is a high-magnification image of the brain metastasis region of breast cancer; Figure 3 The phenotypic changes in lentivirus-mediated knockout of SCARF1 in 231-BR cells as described in Example 1; in, Figure 3 In section A, qRT-PCR is used to verify the efficiency of mRNA knockdown. Figure 3 B represents the efficiency of protein knockdown as verified by Western blot protein immunoblotting. Figure 3 The curve in C represents the proliferation curve of 231-BR cells with knocked-down ScarF1. Figure 3 D represents the scratch healing results of 231-BR cells with knocked-down SCARF1; Figure 4 Transcriptome sequencing and cell adhesion function experiments of cells knocked down SCARF1 (sh-SCARF1) compared to the sh-NC control group as described in Example 1. in, Figure 4 A in the diagram represents the differential gene volcano plot between sh-SCARF1 and sh-NC. Figure 4 B in the diagram represents the GO functional enrichment chord diagram. Figure 4 In the middle, C represents the results of the cell adhesion experiment; Figure 5 This is the result of verifying the nanomedicine uptake capacity of 231-BR cells with SCARF1 knocked out as described in Example 1; in, Figure 5 Image A in the image is a transmission electron microscope (TEM) image of MSN-DOX@PR nanoparticles. Figure 5 Image B shows laser confocal fluorescence microscopy images of sh-NC control group cells and SCARF1 knockdown cells; Figure 6 The MSN-DOX@PR nanomedicine described in Example 1 demonstrates the killing effect of the MSN-DOX@PR nanomedicine on sh-NC control group and sh-SCARF1 knockdown 231-BR cells. in, Figure 6 In section A, cell survival curves are obtained after gradient concentration administration. Figure 6 In section B, cell viability is measured at a fixed drug concentration for different treatment times. Figure 7 This refers to the tumor formation of sh-NC control group and sh-SCARF1 knockdown 231-BR cells in nude mice under the skin, as described in Example 1. in, Figure 7 In the middle, A represents the tumor growth volume curve. Figure 7 B represents the sh-NC control group and sh Images of dissected tumor tissue from the SCARF1 knockdown group. Figure 7 In the middle, C represents the weighing results of the dissected tumors in the sh-NC and sh-SCARF1 groups; Figure 8 To evaluate the in vivo therapeutic effect of the nanomedicine MSN-DOX@PR in the nude mouse subcutaneous tumor model described in Example 1; in, Figure 8 In the middle, A represents the tumor volume growth curve during treatment. Figure 8 Photograph of the tumor removed, with B as the endpoint. Figure 8 The middle C represents the endpoint, a scatter plot of tumor weight. Figure 8 D represents the Kaplan-Meier survival curve for mice. Detailed Implementation
[0045] It should be noted that the following detailed description is illustrative and intended to provide further explanation of the invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0046] It should be noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of exemplary embodiments according to the invention. As used herein, the singular form is intended to include the plural form as well, unless the context clearly indicates otherwise. Furthermore, it should be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations, devices, components, and / or combinations thereof.
[0047] In the context of this invention, the word "comprising" is considered to mean "particularly including". It should not be interpreted as "consisting of only".
[0048] In the description of this invention, it should be understood that the term "and / or" describes the relationship between related objects, indicating that three relationships can exist. For example, A and / or B can represent: A existing alone, A and B existing simultaneously, and B existing alone. The symbol " / " in this document indicates that the related objects are in an "or" relationship; for example, A / B means A or B.
[0049] In the description of embodiments of the present invention, the words "exemplary" or "for example" are used to indicate that they are examples, illustrations, or descriptions. Any embodiment or design that is described as "exemplary" or "for example" in the embodiments of the present invention should not be construed as being more preferred or advantageous than other embodiments or design. Specifically, the use of the words "exemplary" or "for example" is intended to present the relevant concepts in a specific manner.
[0050] In the description of the embodiments of the present invention, unless otherwise stated, "a plurality of" means two or more.
[0051] To enable those skilled in the art to better understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below with reference to specific embodiments.
[0052] The experimental materials, reagents, and reagent formulations involved in the following examples are as follows: Main experimental materials: 1. Tissue: Primary breast cancer tissue and brain metastasis tissue of breast cancer were collected from one patient.
[0053] 2. Primers: All primers used in this invention were synthesized at Sangon Biotech (Shanghai) Co., Ltd.
[0054] 3. Antibodies: The SCARF1 antibody used in this invention was purchased from Cell Signaling Technology, USA, and β-actin was purchased from Santa Cruz, USA.
[0055] Main reagents: 1. Cell Culture Reagents: Triple-negative breast cancer cells MDA-MB-231 and their brain metastases 231-BR were cultured in DMEM. DMEM was purchased from Sigma-Aldrich (USA) and supplemented with 10% fetal bovine serum and 1% dual antibiotics (penicillin and streptomycin). All cell lines were cultured in a constant temperature incubator at 37°C and 5% CO2.
[0056] 2. RNA extraction, reverse transcription and PCR reagents: RNA extraction TRIzol was purchased from ThermoFisher, reverse transcription reagent was purchased from Beijing Beyotime Biotechnology Co., Ltd., and TB Green Premix Ex Taq II kit was purchased from Takara.
[0057] 3. m5C MeRIP: m5C MeRIP reagent was purchased from GenSeq (China). 4. Western blot reagents: Cell lysis buffer RIPA, 30% acrylamide, protein BCA quantitative reagent, PVDF membrane, and skim milk powder were all purchased from Beijing Beyotime Biotechnology Co., Ltd.; ECL developing solution was purchased from Thermo Fisher Scientific and PageRuler (USA). TM The Prestained Protein Ladder was purchased from Thermo Scientific, USA. 5. SCARF1 RNAi-customized-lentiviral particles were purchased from Shanghai Jikai Gene Technology Co., Ltd., and puromycin was purchased from Beijing Beyotime Co., Ltd.
[0058] 6. Immunohistochemical reagents: cleaning solution, dewaxing solution, probe cleaning system, open reagent bottles, printed labels and ribbons, Bond universal coverplates, titration reagent bottles, mixing station, and antigen retrieval solution were all purchased from Leica GmbH, Germany.
[0059] Main reagent formula: 1.50×TBS formulation: Dissolve Tris-base in 800mL double-distilled water, adjust pH to 7.5 with concentrated HCl, and bring the volume to 1000mL with double-distilled water. Store at room temperature.
[0060] 2.10% Ammonium Persulfate: Dissolve 0.1g of ammonium persulfate in 1mL of double-distilled water.
[0061] 3.5% skim milk powder: Dissolve 2.5g of skim milk powder in 50mL TBST.
[0062] Example 1 (a) Detection of differential expression of 231-BR and MDA-MB-231 by RNA sequencing combined with MeRIP-m5C sequencing The study employed next-generation sequencing technology using methylated RNA immunoprecipitation. The specific steps are as follows: 1. RNA-seq: MDA-MB-231 and 231-BR cells were collected, the culture medium was discarded, cells were washed with PBS, and the PBS was discarded. Total RNA was extracted from the cells using the TRIzol method. The concentration and purity of RNA were assessed using a NanoDrop 2000 UV-Vis spectrophotometer, with an OD260 / OD280 ratio between 1.8 and 2.1. To obtain differentially expressed mRNAs between 231-BR and MDA-MB-231 cells, third-generation RNA sequencing technology was used.
[0063] 2. m5C MeRIP-seq: MDA-MB-231 and 231-BR cells were collected, the culture medium was discarded, cells were washed with PBS, and the PBS was discarded. Total RNA was extracted from the cells using the TRIzol method. The concentration and purity of RNA were assessed using a NanoDrop 2000 UV-Vis spectrophotometer, with an OD260 / OD280 ratio between 1.8 and 2.1. Fragmentation buffer was added to fragment the RNA to approximately 100 bp. Magnetic beads were conjugated with m5C antibody, followed by immunoprecipitation with the remaining fragmented RNA, and then the RNA was eluted with free m5C adenosine analogue. RNA MeRIP-seq was performed in triplicate for each group. To obtain the differentially expressed m5C gene between 231-BR and MDA-MB-231 cells, next-generation sequencing using methylated RNA immunoprecipitation was employed.
[0064] The results are as follows Figure 1 As shown, a heatmap analysis was performed on the 40 genes with the most significant differential mRNA expression between 231-BR cells and MDA-MB-231 cells. By integrating m5C MeRIP-seq and RNA-seq data, it was found that compared with the parental breast cancer cells (MDA-MB-231), SCARF1 was highly expressed in breast cancer brain metastases in 231-BR cells, and its m5C methylation level was significantly upregulated. Joint analysis of RNA-seq and m5C MeRIP-seq data revealed 10 common differentially expressed genes, among which SCARF1 showed upregulated mRNA and m5C levels.
[0065] (ii) The expression level of SCARF1 in brain metastases of breast cancer was significantly higher than that in primary breast cancer tissue. SCARF1 expression in brain metastases and primary breast cancer tissues was detected using a Leica Bond Max fully automated immunohistochemical analyzer. The specific steps are as follows: 1. Tissue dehydration, embedding, and sectioning: Breast cancer brain metastases (BCBM) and primary breast cancer (BC) tissue from the patient were cut into appropriately sized blocks and fixed in 4% paraformaldehyde for 48 hours. After fixation, tumor tissue and normal breast tissue were removed and washed with PBS. The tissues underwent gradient dehydration: 70% ethanol for 30 min; 80% ethanol for 30 min; 90% ethanol for 30 min; 95% ethanol I for 30 min; 95% ethanol II for 30 min; anhydrous ethanol I for 30 min; anhydrous ethanol II for 30 min; xylene I for 1 hour; and xylene II for 2 hours. The tissues were then embedded using an embedding machine, trimmed, and sectioned.
[0066] 2. Fully automated immunohistochemistry experiment: Place the tissue sections in a 60℃ incubator for 2 hours for dewaxing. After dewaxing, perform immunohistochemical experiments according to the instruction manual of the Leica Bond Max fully automated immunohistochemistry machine.
[0067] The results are as follows Figure 2 As shown, immunohistochemical experiments revealed that SCARF1 is highly expressed in brain metastases from breast cancer patients and lowly expressed in breast cancer tissue.
[0068] (iii) Lentiviral knockout of SCARF1 in breast cancer brain metastases (231-BR) can inhibit the proliferation and migration of 231-BR. A stable SCARF1 knockout 231-BR cell line was constructed using lentiviral infection. The malignant cellular morphology of the 231-BR cells was detected using CCK-8 assay and scratch assay. The specific steps are as follows: 1. After cells reach the logarithmic growth phase, they are sputtered at a rate of 5 × 10⁻⁶. 4Cell suspension at a density of 2 ml / ml was seeded into 6-well plates and incubated at 37°C with 5% CO2. Lentiviral infection: When the cell density reached 60-70% confluence, the medium was replaced with fresh medium containing 1 ml of fetal bovine serum-free medium containing 40 μl Hitrans GP and an appropriate amount of sh-SCARF1 lentiviral suspension (Jikai Gene, Shanghai), and incubated. After 16 h of culture, the medium was replaced with normal fresh medium for further culture. 72 h after cell infection, the medium was immediately replaced with fresh medium containing 1 μg / ml puromycin, and after 48 h of culture, 231-BR cells with stable SCARF1 knockout were selected. Cell transfection efficiency was observed under a fluorescence microscope, and the success of SCARF1 knockout was further detected by qRT-PCR and Western blot experiments.
[0069] 2. qRT-PCR: Total RNA was extracted using the Trizol (Thermo, USA) method and reverse transcribed into cDNA using a reverse transcription kit (Beyotime, China). The cDNA was then evaluated using the TB Green Premix Ex Taq II kit (Code No. RR820A, Takara, China) with appropriate primers, using β-actin as the standard. Amplification and analysis were performed using a 7500 real-time PCR system (Applied Biosystems, USA).
[0070] 3. Western blot: Cellular proteins were extracted using RIPA reagent (Beyotime, China). Protein concentration was determined using a BCA protein assay kit (Beyotime, China). Proteins were separated by 10-15% SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was then blocked with 5% milk and incubated overnight at 4°C with primary antibodies against SCARF1 (1:1000, #ab92308, Abcam, USA) and β-antin (1:1000, #ab8227, Abcam, USA). After washing the membrane with TBST, it was incubated with enzyme-labeled secondary antibodies (HRP-labeled goat anti-rabbit IgG (H+L), #A0208, Beyotime; HRP-labeled goat anti-mouse IgG (H+L), #A0216, Beyotime) at room temperature for 1 hour, followed by incubation with enhanced chemiluminescence reagent (Thermo Fisher Scientific, USA), and visualized using a chemiluminescence imaging system (Tanon, China).
[0071] 4. CCK-8 experiment: 231-BR (sh-NC or sh-SCARF1) at 3×10 3Cells were seeded in 96-well plates, with 5 replicates per group. 10 μL of CCK-8 solution was added at specific time points (0, 24, and 48 h), and the cells were incubated for another 2 h in a cell culture incubator. The absorbance at 450 nm was measured using a microplate reader. Cell proliferation curves were plotted based on the OD values.
[0072] 5. Cell scratch assay: After cells reach the logarithmic growth phase, seed 2 × 10⁶ cells / year. 5 Cells were transferred to 24-well plates and, when the cells reached 80%-90% confluence, a 1 mL pipette tip was used to make a vertical incision in the 24-well plate. The supernatant was discarded, and low-serum culture medium (containing 2% serum) was added. The cells were photographed under a microscope at this point, recorded as 0 h. Observations and photographs were taken at 24 h and 48 h. The area of the incision in the images was circled using ImageJ to obtain the net optical density value. Cell migration rate = (X h net optical density - 0 h net optical density) / 0 h net optical density * 100%. The higher the value, the lower the migration rate.
[0073] The results are as follows Figure 3 As shown, knocking out SCARF1 in 231-BR cells with lentivirus resulted in decreased cell proliferation and migration compared to the control group (sh-NC), indicating that knocking out SCARF1 in 231-BR cells can inhibit the proliferation and migration of breast cancer brain metastases.
[0074] (iv) Lentiviral knockout of SCARF1 in breast cancer brain metastases (231-BR) upregulates the levels of adhesion-related molecules and enhances the adhesion ability of 231-BR. In this study, third-generation RNA sequencing technology was used to perform transcriptome sequencing on the control group (sh-NC) and the experimental group (sh-SCARF1), and cell adhesion assays were used to detect the effect of knocking out SCARF1 on the adhesion ability of 231-BR cells.
[0075] 1. RNA-seq: Collect sh-NC and sh-SCARF1 cells, discard the culture medium, wash the cells with PBS, and discard the PBS. Extract total RNA from the cells using the TRIzol method. Assess the concentration and purity of RNA using a NanoDrop 2000 UV-Vis spectrophotometer, ensuring the OD260 / OD280 ratio is between 1.8 and 2.1. To obtain differentially expressed mRNA between sh-NC and sh-SCARF1 cells, third-generation RNA sequencing technology was used.
[0076] 2. Cell adhesion assay: Matrigel was diluted 1:400 and seeded into 24-well plates, then incubated overnight at 37°C. The Matrigel was discarded, and the cells were washed with PBS. Cells were then introduced into the plates at a concentration of 3 × 10⁶ cells / well. 4Cells were seeded at a density of 1 / 24 wells and incubated for 30 min, 60 min, and 120 min, respectively. After washing away unattached cells with PBS, the cells were fixed with 4% paraformaldehyde (Solepro, China), stained with 5% crystal violet, and photographed under a microscope.
[0077] The results are as follows Figure 4 As shown, 122 differentially expressed genes were found in sh-NC and sh-SCARF1 cells. Compared with sh-NC, 92 genes were significantly upregulated in sh-SCARF1. GO annotation revealed that the 30 most upregulated genes were closely related to the structure or function of 'collagen-containing extracellular matrix', 'cytoplasmic vesicle lumen', and 'basement membrane'. Furthermore, cell adhesion experiments showed that at 0.5h, 1h, and 2h, the number of adherent cells in the sh-SCARF1 group was greater than that in the sh-NC group, indicating that knocking out ScarF1 enhances the adhesion ability of 231-BR cells to the cell matrix.
[0078] (v) Lentiviral knockout of SCARF1 enhances the uptake of nanomedicines by 231-BR cells.
[0079] A stable SCARF1 knockout 231-BR cell line was constructed using lentiviral infection. A nano-delivery drug, MSN-DOX@PDA-PEG-RGD (MSN-DOX@PR), was prepared. Cellular uptake assays were used to detect the uptake capacity of the nano-drug by 231-BR cells. The specific steps are as follows: 1. Preparation of MSN-DOX@PR: (1) Preparation of silica nanoparticles: 4 g of hexadecyltrimethylammonium chloride (CTAC, Maclean's, China) and 0.16 g of triethylamine (TEA, Maclean's, China) were weighed, and 40 mL of ultrapure water were added. The mixture was stirred at 95 °C for 1 h. Then, 3 mL of tetraethyl silicate (TEOS, Maclean's, China) was slowly added dropwise, and the reaction was continued for 1 h. After centrifugation and washing, anhydrous ethanol was added to wash the precipitate. Finally, the washed product was dried under a nitrogen stream to obtain MSN.
[0080] (2) Doxorubicin loading: Weigh 4 mg of doxorubicin (DOX, Aladdin, China), 1 mL of ultrapure water, and 4 mg of MSN. Place them in a magnetic stirrer and rotate at room temperature in the dark for 24 h. After centrifugation and washing, MSN-DOX is obtained.
[0081] (3) Polydopamine coating: Then add 1 mL Tris-HCl (pH=8.5) and 4 mg dopamine (DA, Sigma, USA), rotate at room temperature in the dark for 4 h, centrifuge and wash to obtain MSN-DOX@PDA; (4) Targeted ligand modification: Then add 1 mL Tris-HCl (pH=8.5) and 4 mg SH-PEG-RGD (2k, Shanghai Tuoyang, China), rotate at room temperature in the dark for 6 h, and obtain MSN-DOX@PR after centrifugation and washing.
[0082] 2. Characterization of MSN-DOX@PR: The morphology and size of MSN-DOX@PR were examined using a transmission electron microscope (JEM-2010, JEOL, Japan).
[0083] 3. Cell uptake experiment: Take 2×10 4 Cells in the logarithmic growth phase were seeded in 24-well plates, with 500 μL of 40 μg / mL MSN-DOX@PR solution added to each well. Cells were cultured for 0, 2, 4, and 6 h, respectively. After washing twice with PBS, 4% paraformaldehyde was added for fixation. After washing again with PBS, Hoechst working solution (Beyotime, China) was added, and the cells were then observed and photographed under a fluorescence microscope (BX53+DP80, Olympus, Japan).
[0084] The results are as follows Figure 5 As shown, MSN-DOX@PR has a nearly spherical appearance and a size of approximately 120 nm. Cell uptake experiments showed that the red fluorescence intensity of DOX in cells of the sh-SCARF1 group was significantly higher than that of the sh-NC group, indicating that knocking down SCARF1 can effectively promote the uptake of nanomedicines by brain metastases from breast cancer.
[0085] (vi) Lentiviral knockout of SCARF1 in the blood enhances the sensitivity of 231-BR cells to nanomedicines.
[0086] This example uses lentiviral infection to construct a stable SCARF1 knockout 231-BR cell line, and cell viability assays are used to detect the toxicity of the nanodelivered drug MSN-DOX@PR to 231-BR cells. The specific steps are as follows: 1. Cell half-life assay: 231-BR (sh-NC or sh-SCARF1) at 3×10⁻⁶ 3Cells were seeded in 96-well plates, with 5 replicates per group. After cell adhesion, different concentrations of MSN-DOX@PR (0, 10, 20, 30, 40 μg / mL) were added to each well. After 48 h of culture, the supernatant was discarded, and 10 μL of CCK-8 (Solepro, China) and 90 μL of culture medium were added to each well. After incubation for another 2 h, the absorbance of each well was measured at 450 nm using a microplate reader. The half-maximal concentration (MCC) of cells in the sh-NC and sh-SCARF1 groups was calculated based on the OD values.
[0087] 2. Cell viability assay: 231-BR (sh-NC or sh-SCARF1) at 3×10⁻⁶ cells / mL. 3 Cells were seeded in 96-well plates, with 5 replicates per group. After cell adhesion, MSN-DOX@PR (20 μg / mL) was added to each well. After co-incubation for 0, 2, 4, and 6 hours, the supernatant was discarded, and 200 μL of regular culture medium was added to each well for 48 hours. Subsequently, the culture medium was discarded, and 10 μL of CCK-8 (Solepro, China) and 90 μL of culture medium were added to each well. Incubation was continued for 2 hours, and the absorbance at 450 nm was measured using a microplate reader. Cell viability was calculated for the sh-NC and sh-SCARF1 groups based on the OD values.
[0088] The results are as follows Figure 6 As shown, the IC of the sh-SCARF1 group 50 The value was significantly lower than that of the sh-NC group (28.63 μg / mL vs 36.92 μg / mL, p<0.0001). After co-incubation with nanomedicine for 6 h, the cell viability of the sh-SCARF1 group was significantly lower than that of the sh-NC group (59% vs 87%, p = 0.0029). These results indicate that silencing SCARF1 can enhance the sensitivity of cells to nanomedicine.
[0089] (vii) Lentiviral knockout of SCARF1 in breast cancer brain metastases (231-BR) can inhibit subcutaneous tumorigenesis in nude mice. In vivo experiments were conducted using 6-week-old female BALB / cA-nu nude mice. The specific steps are as follows: 1. Construction of a subcutaneous xenograft model: Twelve 6-week-old female BALB / cA-nu nude mice (Henan Skebers Biotechnology Co., Ltd., China) were randomly divided into two groups. Cells from the sh-NC group and the sh-SCARF1 group were injected at a rate of 2×10⁻⁶ cells / mL. 6 100 μL of the solution was resuspended in PBS (Solepro, China) and injected into the skin on the right back of nude mice.
[0090] 2. Observe the growth and mental state of the nude mice daily. Measure the weight and subcutaneous tumor size of the mice every three days using calipers. The tumor volume is calculated using the following formula: Volume (mm²) 3= Length (mm) x Width 2 X Width 2 (mm 2 ) / 2.
[0091] 3. On day 18, mice were euthanized under deep anesthesia, and tumors were removed, photographed, and their weight measured. Experimental results are as follows Figure 7 As shown, inhibiting SCARF1 effectively hindered tumor progression. The tumor volume in the sh-SCARF1 group was significantly smaller than that in the sh-NC group (p = 0.0004), and the tumor weight was also significantly reduced (p = 0.0314). The difference in tumor volume between the sh-NC group and the sh-SCARF1 group was statistically significant (p < 0.0001).
[0092] (viii) Knockdown of SCARF1 combined with MSN-DOX@PR synergistically inhibits tumor growth and prolongs survival in vivo.
[0093] In vivo experiments were conducted using 6-week-old female BALB / cA-nu nude mice. The specific steps are as follows: 1. Construction of a subcutaneous xenograft tumor model: Eighteen 6-week-old female BALB / cA-nu nude mice (Henan Skebers Biotechnology Co., Ltd., China) were randomly divided into three groups: sh-NC+MSN-DOX@PR group, sh-SCARF1+MSN-DOX@PR group, and sh-SCARF1+DOX group. sh-NC and sh-SCARF1 cells were inoculated at 2×10⁻⁶ cells per cell line. 6 100 μL of the solution was resuspended in PBS (Solepro, China) and injected into the skin on the right back of nude mice.
[0094] 2. Tail vein treatment: Observe the growth and mental state of nude mice daily. Starting on the seventh day after tumor inoculation, inject DOX (2 mg / kg) or MSN-DOX@PR (4 mg / kg) every three days. Measure the weight and tumor size of the nude mice before each injection. Tumor volume is calculated using the following formula: Volume (mm²) 3 = Length (mm) x Width 2 X Width 2 (mm 2 ) / 2.
[0095] 3. On day 18, mice were euthanized under deep anesthesia, and the tumors were removed, photographed, and weighed.
[0096] Experimental results are as follows Figure 8As shown, the tumor volume (mean 91.7 mm³) in the sh-SCARF1 + MSN-DOX@PR treatment group was significantly smaller than that in the sh-NC + MSN-DOX@PR group (312.6 mm³) and the sh-SCARF1 + free DOX group (135.6 mm³). Ex vivo tumor weighing further confirmed that the tumor weight in the sh-SCARF1 + MSN-DOX@PR group (0.093 g) was significantly lower than that in the sh-SCARF1 + DOX group (0.238 g, p = 0.038). During treatment, there were no statistically significant differences in body weight among the sh-NC + MSN-DOX@PR, sh-SCARF1 + MSN-DOX@PR, and sh-SCARF1 + DOX groups, and survival analysis showed that the survival time of mice in the sh-SCARF1 + MSN-DOX@PR group was significantly prolonged. This indicates that SCARF1 silencing can significantly enhance the in vivo antitumor effect of MSN-DOX@PR and prolong the survival of mice.
[0097] In summary, this invention provides an in-depth study of the role of SCARF1 in the progression of brain metastases in triple-negative breast cancer, clarifying its anti-tumor function in brain metastatic cells (231-BR) of triple-negative breast cancer and its ability to enhance the uptake and sensitivity of nanoparticle-based drug delivery systems. This invention offers a novel explanation of the function of SCARF1, providing new insights for future drug development and treatment, and possesses significant social and market potential.
[0098] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.
Claims
1. The application of SCARF1 as a prognostic biomarker for breast cancer, characterized in that, The specific application is the use of the SCARF1 gene or its expression product in the preparation of breast cancer prognostic assessment reagents / kits; the breast cancer is preferably triple-negative breast cancer, and more preferably triple-negative breast cancer with brain metastasis.
2. A polynucleotide that specifically downregulates SCARF1 expression, characterized in that, Its nucleotide sequence is shown in SEQ ID NO:
1.
3. A construct for inhibiting or downregulating SCARF1 expression, characterized in that, The construct is built by inserting the polynucleotide of claim 2 into the multiple cloning site of the expression vector.
4. A recombinant vector that inhibits or downregulates SCARF1 expression, characterized in that, The recombinant vector includes the construct described in claim 2 or claim 3; The recombinant vectors in this invention include, but are not limited to: plasmid vectors, lentiviral vectors, adenovirus vectors, adeno-associated virus vectors, and retroviral vectors; preferably, lentiviral vectors.
5. A nano-delivery drug, characterized in that, The method for preparing the nanodelivered drug includes the following steps: (1) Preparation of silica nanoparticles: hexadecyltrimethylammonium chloride was used as a template agent and triethylamine as an alkaline catalyst. The nanoparticles were dispersed in ultrapure water and heated and stirred. Then, tetraethyl orthosilicate was added dropwise to carry out hydrolysis and polycondensation reaction. The reaction product was centrifuged, washed and dried to obtain MSN. (2) Doxorubicin loading: The obtained silica nanoparticles and doxorubicin were dispersed in ultrapure water, and the drug was adsorbed and loaded by stirring at room temperature in the dark. The precipitate was collected by centrifugation to obtain MSN-DOX; (3) Polydopamine coating: The MSN-DOX obtained in step (2) was resuspended in buffer solution, dopamine was added, and the mixture was stirred at room temperature in the dark to allow dopamine to polymerize in situ on the surface of the nanoparticles to form a polydopamine coating. The precipitate was collected by centrifugation to obtain MSN-DOX@PDA. (4) Targeted ligand modification: SH-PEG-RGD was added to the MSN-DOX@PDA and surface covalent grafting reaction was carried out by stirring at room temperature in the dark. After the reaction was completed, the surface was purified by centrifugation to obtain MSN-DOX@PR.
6. The nanodelivered drug as described in claim 5, characterized in that, In step (1), the molar ratio of hexadecyltrimethylammonium chloride, triethylamine and tetraethyl orthosilicate is 10~14:1:10~14, more preferably 12:1:12.5; After the hexadecyltrimethylammonium chloride and triethylamine are thoroughly mixed in water at 80-100°C, tetraethyl silicate is slowly added and the reaction continues for 0.5-2 hours. After the reaction is completed, the reaction system is centrifuged to obtain the precipitate, which is the silica nanoparticle. In step (2), the mass ratio of silica nanoparticles to doxorubicin is 0.8~1.2:0.8~1.2; the stirring time in the dark is 3~5 hours. In step (3), the mass ratio of MSN-DOX to dopamine is 0.8~1.2:0.8~1.2, more preferably 1:1; the in-situ polymerization reaction time is 3~5h, more preferably 4h; the light-protected stirring and loading time is 18~30h, more preferably 24h. In step (4), the mass ratio of the thiol-modified polyethylene glycol (PEG)-modified RGD peptide to the silica nanoparticles is 0.8~1.2:0.8~1.2; the PEG segment of the PEG-modified RGD peptide has a molecular weight of 1000~3000 Da, more preferably 2000 Da. The covalent grafting reaction time is 5~7 h, more preferably 6 h.
7. A pharmaceutical composition, characterized in that, The active ingredient comprises a therapeutically effective dose of an active ingredient and a pharmaceutically acceptable carrier; the active ingredient is selected from any one or a combination of the following: the polynucleotide that specifically downregulates SCARF1 as described in claim 2, the nucleic acid construct as described in claim 3, the recombinant carrier as described in claim 4, and the nanodelivery drug as described in claim 5.
8. The use of the SCARF1 inhibitor, the polynucleotide that specifically downregulates SCARF1 according to claim 2, the nucleic acid construct according to claim 3, the recombinant vector according to claim 4, the nanodelivery drug according to claim 5, and the pharmaceutical composition according to claim 6 in the preparation of an anti-breast cancer drug.
9. The application as described in claim 8, characterized in that, The breast cancer in question is further described as triple-negative breast cancer, and even further, as triple-negative breast cancer with brain metastasis.
10. The application as described in claim 8, characterized in that, The anti-breast cancer drug is a SCARF1 inhibitor, and further, it is the polynucleotide that specifically downregulates SCARF1 as described in claim 2, the nucleic acid construct as described in claim 3, or the recombinant vector as described in claim 4; Alternatively, the anti-breast cancer drug is a combination of a SCARF1 inhibitor and a breast cancer treatment drug, wherein the breast cancer treatment drug is the nanodelivered drug as described in claim 5; The anti-breast cancer drug is administered to mammals, preferably humans, via intravenous injection, intratumoral injection, or intrathecal injection.
